Table 6.
Cox proportional hazards analyses testing the count of CNV as a predictive variable for OS
| Independent segments (n=9) |
Independent CLL-specific segments (n=1) |
|||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P variable | P overall model (Likelihood ratio test) | HR | 95% CI | P variable | P overall model (Likelihood ratio test) | |
| Count of CNV as a continuous variable | 2.7 | 1.8–4.1 | 1.5 × 10−6 | 3.5 × 10−7 | 3.0 | 1.3–7.1 | 0.0133 | 0.0093 |
| Count of CNV as a categorical variable | 3.8 × 10−7 | NA | NA | NA | ||||
| 1 CNV | 2.6 | 1.3–5.4 | 0.0083 | |||||
| 2 CNV | 7.6 | 3.3–17.2 | 1.4 × 10−6 | |||||
| Count of CNV as a continuous variable compared to unfavorable cytogenetics | 6.0 × 10−6 | 7.6 × 10−7 | 0.0173∗ | 0.0058 | ||||
| Count of CNV | 2.7 | 1.8–4.1 | 2.2 × 10−6 | 3.4 | 1.4–8.4 | 0.0066 | ||
| Del6q21 and/or del17p13 | 1.7 | 0.8–3.6 | 0.1630 | 2.1 | 1.0–4.5 | 0.0549 | ||
| Count of CNV as a categorical variable compared to known prognostic variables | 3.9 × 10−6 | 7.3 × 10−11 | 0.0449∗ | 1.2 × 10−6 | ||||
| 1 CNV | 3.0 | 1.4–6.4 | 0.0036 | 2.7 | 1.1–6.7 | 0.0250 | ||
| 2 CNV | 7.6 | 3.1–18.4 | 7.4 × 10−6 | NA | NA | NA | ||
| Unmutated/GHV status | 1.7 | 0.8–3.5 | 0.1537 | 2.2 | 1.1–4.5 | 0.0278 | ||
| High B2M | 2.1 | 1.1–4.2 | 0.0246 | 2.2 | 1.2–4.3 | 0.0147 | ||
| Del6q21 and/or del17p13 | 4.0 | 1.8–9.0 | 0.0005 | 2.7 | 1.3–5.7 | 0.0104 | ||
CI, confidence interval; HR, hazard ratio; n, number of patients; NA, not applicable; p, p-value.
∗
P-values for the significance of addition of the CNV count to clinical variables was tested using an analysis of deviance and is based on the χ2 statistic.